ArticleCost effectiveness and resource allocation : C/E2018

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom.

Gabriel Tremblay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.